Physician profile
Tanner E Mcdaniel
NPI 1669458451
$8,701.37
in general payments reported to CMS, 2019-2025
35 companies · $833 in 2025
The $833 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $1,058 · 2021: $1,887 · 2022: $1,359 · 2023: $1,029 · 2024: $1,210 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,549.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,267.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,118.68 | 2021-2025 | |
| Lilly USA, LLC | $997.88 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.71 | 2019-2025 | Jardiance |
| Pfizer INC. | $395.17 | 2020-2025 | |
| Allergan, INC. | $345.44 | 2019-2020 | |
| Amgen INC. | $246.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $231.34 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $218.35 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Exact Sciences Corporation | $184.55 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $168.53 | 2020-2022 | |
| Astellas Pharma US INC | $168.24 | 2019-2022 | |
| Abbott Laboratories | $148.44 | 2022-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $126.94 | 2019-2023 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $121.53 | 2022-2025 | |
| Kaleo, INC. | $118.33 | 2020-2021 | |
| Eisai INC. | $84.28 | 2020-2021 | |
| Boston Scientific Corporation | $77.08 | 2019-2024 | |
| Idorsia Pharmaceuticals US INC | $76.58 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $66.76 | 2019-2024 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $66.30 | 2021 | |
| Horizon Therapeutics Plc | $58.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $53.89 | 2020-2021 | |
| Esperion Therapeutics, INC. | $47.61 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $26.14 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.24 | 2024 | Caplyta |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.42 | 2022 | |
| Aimmune Therapeutics, INC. | $18.24 | 2025 | Zenpep |
| Relievant Medsystems, INC. | $17.46 | 2022 | |
| Almatica Pharma LLC | $16.09 | 2023 | Gralise, Loreev Xr |
| Medtronic USA, INC. | $12.49 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanner Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.